MetaCap

BioNexus Gene Lab Insider Trades

NASDAQ: BGLCHealth CareMedical SpecialitiesUSD

0.680.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
0 · $0
Shares bought / sold
0 / 0
Net activity
Net buying $0

BioNexus Gene Lab insider activity

Over the last 12 months, BioNexus Gene Lab insiders reported 5 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Tan Lee Su-Leng (Chief Executive Officer) reporting a transaction in 338,709 shares on Aug 13, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put BGLC's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

BGLC insider transactions

BioNexus Gene Lab insider transactions
DateInsiderTypeSharesValueFiling
Aug 13, 2026Low Jook YuenDirectorAward16,129—Form 4
Aug 13, 2026Chong Set FuiChief Financial OfficerAward96,774—Form 4
Aug 13, 2026Yap Chee KeongDirectorAward32,258—Form 4
Aug 13, 2026Bin Abdul Hamid Muhammad AzrulDirectorAward32,258—Form 4
Aug 13, 2026Tan Lee Su-LengChief Executive OfficerAward338,709—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related